I am a board-certified gynecologic oncologist dedicated to caring for and surgically treating women with cancerous and noncancerous diseases of the gynecologic/female genital tract. I have been an attending surgeon at Memorial Sloan Kettering for more than 17 years and, due to my dedication to and experience in caring for women with gynecologic cancers, was appointed Deputy Chief of the Gynecology Service in 2010.
My areas of particular expertise include the use of minimally invasive surgery to diagnose and treat women with early-stage gynecologic cancers, as well as those with nonmalignant gynecologic conditions. I also have a special interest in the use of innovative surgical techniques and technology to improve outcomes for women with early, advanced, or recurrent cancers of the ovaries, uterus, cervix, vagina, or vulva. When appropriate, I offer my patients newer treatment modalities such as sentinel node biopsy, fertility-preserving surgery, and robotic surgery, as well as panniculectomies (removal of excess fat from the lower abdomen), which result in better surgical outcomes and improved cosmesis of the abdomen.
Over the past 20 years, I have dedicated much of my research to exploring ways to expand and improve our surgical management of patients with ovarian, fallopian tube, and peritoneal cancer. My work has led to my being the lead investigator on dozens of studies that have demonstrated the safe use of advanced minimally invasive surgical techniques for the management of early ovarian cancer, as well as the beneficial effects of the use of extensive surgical procedures for advanced disease. I am a firm believer in the comprehensive team approach to the surgical management of ovarian cancer that we take at MSK, and we have numerous publications that have shown that this approach has provided us with patient outcomes that are among the best in the world.
Due to my passion for helping those with this cancer, I was recently named the Head of Ovarian Cancer Surgery. With this new responsibility, I will continue to strive to be an international leader and authority in the field, as well as to passionately pursue advances that will result in the best possible quantity and quality of life for our patients.
Some of our current clinical investigations at MSK include identifying ways to decrease the need for blood transfusions during surgery, utilizing cutting-edge technology to identify microscopic nests of cancer cells, and administering heated chemotherapy directly into the abdomen after removal of cancer implants. I have also worked with international colleagues to establish clinical guidelines for determining appropriate candidates for second and third surgeries in cases of recurrent ovarian cancer. My goal is not only to improve the quality of life and long-term remission for patients with difficult cases of very advanced or recurrent disease but also to offer hope where very little may have existed before.
On a national level, I have served for many years as the Director of the Society of Gynecologic Oncology’s annual postgraduate surgical courses aimed at instructing gynecologic oncologists throughout the world on the most up-to-date surgical treatments for women with gynecologic malignancies. I am a board examiner for the American Board of Obstetrics and Gynecology and a member of the gynecologic cancer task force for the American Joint Commission on Cancer. I am currently editing, along with colleagues from the University of California, Irvine, and UCLA, the third edition of a textbook entitled Surgery for Ovarian Cancer: Principles and Practice and have just completed editing the first edition of another textbook entitled Radical and Reconstructive Gynecologic Cancer Surgery. I have served as the President of the Society of Memorial Gynecologic Oncologists and the Metropolitan Gynecologic Cancer Society.
On an international level, I am one of a handful of gynecologic oncology surgeons from the United States on the faculty of Esagon (European School of Abdomino-pelvic Surgery in Gynecologic Oncology), based in Italy. The school provides surgeons throughout the world with the ability to interact with and learn from leading experts in the complex field of gynecologic oncology surgery. Our passionate mission is to improve the care and outcomes of women with gynecologic cancers — not just in our own countries, but everywhere.
- Clinical Expertise: Gynecologic Oncology; Cancers of the Cervix, Uterus, Ovary, and Vulva
- Awards and Honors: New York Magazine Top Doctors (2012-2016)
- Languages Spoken: English
- Education: MD, New York University School of Medicine
- Residencies: New York University School of Medicine
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Obstetrics and Gynecology; Gynecologic Oncology
Surgery for Ovarian Cancer: Principles and Practice. 2nd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2010.
Selected Book Chapters
“Cancer of the ovary, peritoneum, and fallopian tube.” Chi DS, Kauff ND. In: PRECIS: Oncology. 3rd ed. Danvers MA: American College of Obstetricians and Gynecologists; 2007: 88-100.
“Cervical cancer.” Chi DS, Perez CA, Kavanagh J. In: Cancer Management: A Multidisciplinary Approach. 11th ed. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Norwalk, CT: UBM Medica; 2008: 465-496.
“Pelvic exenteration.” Levine DA, Bochner BH, Chi DS. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rustum NR, eds. London: Informa Healthcare; 2008: 93-116.
“Extended pelvic resection.” Diaz JP, Boland PJ, Chi DS, Abu-Rustum NR. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rusturn NR, eds. London: Informa Healthcare; 2008: 137-144.
“Hand-assisted laparoscopic splenectomy.” Diaz JP, Chi DS. In: Atlas of Procedures in Gynecologic Oncology. 2nd ed. Levine DA, Barakat RR, Abu-Rustum NR, eds. London: Informa Healthcare; 2008: 267-270.
“Surgical principles in gynecologic oncology.” Chi DS, Gallup DG, Bristow RE. In: Principles and Practice of Gynecologic Oncology. 5th ed. Barakat RR, Markman M, Randall ME, eds. Philadelphia: Lippincott, Williams & Wilkins; 2009: 269-287.
“Secondary cytoreductive surgery.” Bristow RE, Chi DS. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2010: 218-234.
“Advanced cytoreductive surgery program development: building a cytoreductive team.” Zivanovic 0, Chi DS, Karlan BY. In: Surgery for Ovarian Cancer: Principles and Practice. 2nd ed. Bristow RE, Karlan BY, Chi DS, eds. New York: Informa Healthcare; 2010: 291-300.
“Video-assisted thoracic surgery.” Eitan R, Chi DS. In: Textbook of Gynaecological Oncology. 2nd ed. Ayhan A, Reed N, Gultekin M, eds. Ankara, Turkey: Gunes Publishing; 2011.
“Secondary cytoreduction in the treatment of recurrent ovarian cancer.” In: Textbook of Gynaecological Oncology. 2nd ed. Ayhan A, Reed N, Gultekin M, eds. Ankara, Turkey: Gunes Publishing; 2011.
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more